Overview of LevaMed

Quick Facts

Property	Description
Active ingredient	Levamisole (hydrochloride salt)
Form	Oral tablet, Oral solution (Prescription)
Pharmacological class	Anthelmintic, Immunomodulatory Agent
Common purpose	Clearance of parasitic worms, Immune system support
Origin	Synthetic (L-isomer of Tetramisole)

Defining LevaMed: A Synthetic Dual-Action Agent

LevaMed is a prescription medication whose active substance is the International Nonproprietary Name (INN) compound Levamisole, a synthetic Imidazothiazole derivative. This drug possesses a distinct dual pharmacological classification, setting it apart from other medicines, as it is utilized both as a fast-acting Anthelmintic (anti-worm agent) and a unique Immunomodulatory Agent. Supported by pharmacological studies, its core anti-parasitic efficacy is clinically recognized for specific nematode infections.

What Pharmacological Class Does Levamisole Belong To?

Levamisole is characterized by its dual role, but its primary distinction as an anthelmintic lies in its mechanism: it functions as a potent nicotinic agonist, which induces spastic paralysis in the parasitic worm, facilitating rapid expulsion. This specific action contrasts with other worm treatments that target metabolic processes. Its inclusion on the WHO Essential Medicines List confirms the medicine's global public health relevance for treating soil-transmitted helminthiasis. Furthermore, Levamisole's secondary capacity to modulate the immune system has been extensively studied, noting that it may restore depressed immune function by enhancing T-cell and macrophage activity.

Composition, Form, and General Purpose

As a single-ingredient synthetic entity, Levamisole is formulated for oral administration, primarily available as an oral tablet or an oral solution. The fundamental therapeutic goal of LevaMed therapy is the swift, definitive elimination of parasitic organisms. The compound's unique, well-documented capacity to support and enhance the body's natural immunological capacity also forms a key part of its overall therapeutic profile in specific medical contexts.

Regulatory References

WHO Essential Medicines List for Levamisole

What side effects are possible with LevaMed?

Possible Side Effects and Safety Information for LevaMed

This section outlines the officially documented side effects and safety information for LevaMed, based strictly on government regulatory documents.

Adverse Reaction Scope

Adverse reactions are formally categorized by frequency using the MedDRA convention and grouped by System-Organ Class (SOC) to identify affected body systems.

Frequency Classification	Examples of Reactions
Very Common (ge 1/10)	Headache, Insomnia
Common (ge 1/100 to < 1/10)	Nausea, Dizziness, Fatigue
Uncommon (ge 1/1,000 to < 1/100)	Elevated Liver Enzymes (AST/ALT), Vertigo, Rash
Rare (ge 1/10,000 to < 1/1,000)	Angioedema, Tachycardia

System-Organ Classes Involved: Reactions are documented across various systems, including Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions: Regulatory documentation highlights risks such as Severe Hypersensitivity Reaction (including Angioedema), Hepatotoxicity, Agranulocytosis, and Prolongation of the QT interval. Periodic monitoring of liver function tests (LFTs) is mandated during the first year of treatment.

Population-Specific Considerations: Specific safety statements exist for vulnerable groups. Elderly patients and those with Renal Impairment (creatinine clearance below 30 mL/min) may require dosage adjustments due to potential drug accumulation.

Safety Restrictions: LevaMed is contraindicated in patients with a history of Angioedema related to this drug class, pre-existing Severe Hepatic Impairment, or Uncontrolled Tachyarrhythmias. It requires ECG monitoring for patients with pre-existing cardiac arrhythmias.

Exposure-Related Patterns: Gastrointestinal adverse reactions are documented as significantly more frequent during the first month of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

If an overdose of LevaMed (Levamisole) is suspected, seek emergency medical attention immediately, as required by government regulatory bodies. Hospital treatment is generally necessary due to the risk of severe complications.

Documented Overdose Presentations

Acute overdose is characterized by signs of cholinergic toxicity (nicotine-like effects), including:

Excessive sweating and increased salivation
Muscular tremors and loss of muscle control (ataxia)
Irritability, confusion, and seizures or convulsions

Severe Systemic Risks

Regulatory safety reviews and prescribing information indicate that severe, prolonged, or high-dose exposure carries the risk of life-threatening systemic outcomes:

Agranulocytosis: A dangerous drop in white blood cell count that impairs the body's ability to fight infection and has been reported as fatal.
Encephalopathy/Leukoencephalopathy: Severe brain disease, including damage to the brain's white matter, which is classified as a potentially life-threatening complication.

Required Emergency Actions

Treatment is officially defined as symptomatic and supportive. There is no specific human antidote universally recognized in regulatory labeling. Procedural steps listed in official documents that may be beneficial if performed shortly after ingestion include:

Emesis (inducing vomiting) or gastric lavage (stomach pump).

Risk of severe toxicity is amplified in patients with pre-existing blood disorders or advanced liver or kidney disease.

Therapeutic Uses of LevaMed

The substance levamisole has been relevant across several therapeutic areas. The substance is considered relevant not only for its primary action but also historically in certain situations involving immune support.

LevaMed may be part of symptomatic management for acute or episodic manifestations, symptoms related to physical discomfort, and conditions where functional stability becomes affected.

Support for Symptom Management

LevaMed is applied across domains where additional symptomatic support is needed. It assists with maintaining a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load during difficult episodes. The medication supports general well-being during symptomatic phases.

Addressing Disruptive Symptom Patterns

LevaMed is commonly used when short-term symptomatic assistance is needed to help with symptom clusters that may become intense or disruptive. It is often applied during phases where symptoms intensify and supportive relief is needed, providing support that helps ease the overall symptom burden.

Supporting Comfort During Fluctuations

LevaMed is applicable in conditions characterized by periods of heightened symptoms or those involving episodic or fluctuating manifestations. It contributes to improved day-to-day comfort during symptomatic periods and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Symptomatic Support for Disruptive Patterns

Eligibility and Restrictions for Use

Eligibility Scope

Population Status	Regulatory Rule
Populations for whom use is allowed (as stated in label)	Adult and pediatric patients for established anthelmintic uses, where permitted by regional regulatory guidelines.
Populations for whom use is not recommended (if applicable)	Women who are pregnant or breastfeeding; use is restricted to cases where the clinical benefit formally outweighs the potential risk.
Populations for whom use is contraindicated	Patients with a known hypersensitivity to levamisole or any excipients. Individuals with a history of blood dyscrasias (e.g., agranulocytosis) linked to previous levamisole therapy.

Age-related and Condition-Specific Eligibility

Age-related eligibility rules: Safety and effectiveness for non-anthelmintic uses may be not established or may lack specific information in certain pediatric age groups. Geriatric use is not expected to cause different side effects but warrants caution due to potential changes in organ function.
Condition-specific eligibility rules: Use is not recommended or requires caution in patients with severe hepatic or renal impairment. Individuals with pre-existing infections or other conditions where immune response is critical require special consideration due to the drug's activity.

Eligibility-Related Restrictions

The official eligibility structure imposes a Prior History Constraint, absolutely prohibiting use in patients with a history of severe levamisole-associated hematological events. Eligibility is also subject to Physiological State Constraints (pregnancy, lactation) and restrictions based on the patient's current organ function or immune status, as documented in governmental prescribing information.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use LevaMed by setting absolute prohibitions based on hypersensitivity and a history of specific blood disorders. Beyond these contraindications, eligibility is further restricted for distinct population categories—notably children, pregnant women, and patients with compromised organ function—by stating that use is either "not recommended" or requires careful judgment against potential risks, according to governmental labeling.

What should I know about interactions with other medicines?

The official regulatory profile for LevaMed (Levamisole) establishes multiple interaction constraints based on pharmacokinetic (PK) and pharmacodynamic (PD) effects on co-administered substances. These documented interactions necessitate specific restrictions or monitoring requirements.

Major Interaction Restrictions and Timing Rules

Interacting Substance	Regulatory Constraint or Outcome
Organophosphorus Compounds	Treatment is formally restricted by a 14-day mandatory separation period to prevent enhanced toxic effects.
Alcohol (Ethanol)	Must be avoided due to the officially described potential for a disulfiram-like reaction (e.g., severe headache, vomiting).
Highly Lipophilic Preparations	Co-administration is prohibited as it carries the documented risk of increased Levamisole toxicity.
Antihistamine Containing Products	Co-administration is formally restricted in regulatory documentation.

Pharmacokinetic and Exposure Alterations

The drug is formally documented to alter the systemic exposure of several co-administered medicines. Co-administration with coumarin-type anticoagulants (e.g., Warfarin) is documented to potentiate their effect, leading to prolonged prothrombin time. Levamisole also increases the plasma concentration of Phenytoin. Furthermore, Levamisole alters the bioavailability of other anti-parasitic agents, officially increasing the bioavailability of Ivermectin while decreasing the bioavailability of Albendazole. No known interaction with food is documented in regulatory summaries. These constraints define specific regulatory requirements for co-administration.

Mechanism of Action

LevaMed (levamisole) acts as an agonist at the L-subtype nicotinic acetylcholine receptors found on muscle cells in target organisms. The drug's binding to these ionotropic receptors induces prolonged and sustained depolarization of the post-synaptic muscle membrane. This depolarization leads to an uncontrolled, continuous influx of sodium ions through the activated receptors. The resulting excessive excitation causes persistent muscle contraction, culminating in spastic paralysis of the organism's musculature. Separately, levamisole exhibits immunomodulatory effects through mechanisms that include increasing the proliferation and activation of T-lymphocytes and enhancing the function of macrophages and neutrophils. This intracellular cascade involves the modulation of various signaling pathways within immune cells, resulting in a systemic shift in the cellular and humoral components of the immune response.

Dosage and Administration Information

How to Use LevaMed: Official Administration Guidelines

LevaMed (levamisole) is officially administered via the oral route, typically available as an oral tablet or oral solution. The general usage pattern is highly dependent on the medical application, leading to distinct, label-based dosing schedules.

Instruction	Detail
Route of administration:	Oral
Dosing schedule:	Single Dose: 120 mg to 300 mg for adults, or 2.5 mg/kg for pediatric use, often for short-course treatment. Cyclic Regimen: An alternate-day frequency (2.5 mg/kg every other day) is employed for certain long-term maintenance protocols.
Preparation and Timing:	Tablets should be swallowed with a liquid (such as water or juice) and may be crushed and mixed with soft food for ease of intake. The medication is usually taken at the same time each day on its scheduled administration day.
Population-specific rules:	Weight-based dosing applies to children. For patients with renal impairment, the dose typically remains as normal. Official regulatory documents indicate that specific human dose adjustment data for hepatic impairment is unavailable.

The procedural structure involves adhering strictly to either the rapid, single-dose course, where a maximum adult dose of 300 mg may be taken once, or the complex, intermittent cyclic regimen, which can extend over a period of many months. If a dose is missed during an alternate-day schedule, the official instruction is to take the dose as soon as remembered on the due day, immediately resuming the normal every-other-day pattern. These rules establish the standardized framework for use as defined by government regulatory authorities.

Recent Clinical Evidence

Research Evidence / Overview of Studies for LevaMed

Evidence for Use in Parasitic Worm Clearance

The primary research for Levamisole's initial purpose was evaluated in short-term, controlled studies designed to explore its activity against common parasitic worm infections, such as soil-transmitted helminths. These Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews included populations primarily consisting of children and adults who had confirmed parasitic infections. The main goal of this research was to measure specific outcomes like the Fecal Egg Count Reduction Rate and the proportion of subjects who showed no remaining eggs after treatment.

Studies consistently reported patterns showing that within the short-term follow-up periods (ranging from days to a few weeks), a high number of subjects reached the endpoint of absence of parasitic eggs or microfilariae in their samples. Field-based research and meta-analyses contribute to the broader evidence landscape, describing patterns of activity against the specified intestinal nematodes. Long-term outcomes are not fully established, as follow-up durations were often limited to confirming the initial measurement.

Evidence for Use in Immune System Support

The research exploring Levamisole's secondary classification as an Immunomodulatory Agent involved different study designs, often requiring medium-to-long-term observation. These studies, including RCTs and follow-up cohorts, research examined its use during periods of increased symptom activity in conditions where systemic or functional imbalance was present. Research primarily examined the substance in specialized contexts, such as using it as an adjunctive treatment in certain chronic conditions like frequently relapsing kidney disorders in children.

Findings from these trials describe patterns observed where the use of Levamisole was associated with differences in the time to first disease flare or the overall frequency of relapse compared to control groups. Certainty remains low for general or widespread immunomodulatory use, as results were mixed and highly dependent on the specific condition studied. Limited long-term data is a continuous challenge, especially concerning the sustained use required for immune modulation.

What Scientific Sources Cite as Research Gaps

Authoritative scientific sources describe several areas where knowledge of Levamisole remains uncertain or incomplete. A primary gap is the inconsistency and heterogeneity of findings across the various immune-mediated conditions it was studied for; evidence quality varies across studies. Furthermore, comparative evidence is lacking against other therapeutic options that have become available since Levamisole was first introduced. The research landscape highlights what is known—and what is still uncertain—about the full spectrum of Levamisole's effects.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about LevaMed (FAQ)

Q: Can LevaMed cause long-term side effects?

Regulatory documents mention that during long-term use for certain chronic conditions, serious blood disorders like neutropenia and agranulocytosis have been documented. These are considered serious adverse effects. Regulatory texts note that these effects have been described as reversible upon discontinuation of treatment.

Q: Can people with [broad chronic condition, e.g., high blood pressure] use LevaMed?

Official prescribing information emphasizes that caution is necessary for patients with pre-existing conditions like severe blood disorders, kidney impairment, liver impairment, or certain heart conditions. For chronic conditions not specifically listed as contraindications, the determination of eligibility for use necessitates careful consideration of a patient’s full medical history.

Q: What is the expected duration of treatment with LevaMed?

The expected duration of treatment is described in two patterns, dependent on the medical application. The medicine is used either in a rapid, single-dose course for certain anti-parasitic uses, or it is used in a complex, intermittent cyclic regimen that can extend over a period of many months for its immune-modulating purposes.

Q: What are the ingredients in LevaMed tablets/capsules?

The active ingredient in the medication is Levamisole hydrochloride. The complete list of inactive ingredients, known as excipients, used in the commercial tablet or capsule formulation is officially specified in the packaging and description sections of the product information.

Q: What does 'contraindication' mean in relation to LevaMed?

A 'contraindication' refers to a specific condition or factor that absolutely prohibits the use of the drug due to a significantly increased risk. For LevaMed, this includes having a known hypersensitivity (severe allergic reaction) to the drug or a history of certain blood disorders (blood dyscrasias) linked to previous use.

Q: Can LevaMed make other medications less effective?

Regulatory documents confirm that Levamisole can alter the way the body processes other medications. Co-administration is documented to decrease the systemic exposure and effectiveness (bioavailability) of certain other anti-parasitic medicines.

Q: Why do some people stop taking LevaMed?

Discontinuation is described in regulatory documents for several reasons. People stop using the medicine either because the specified short course of treatment is completed or due to the occurrence of adverse reactions that are severe or intolerable, such as agranulocytosis, which leads to discontinuation.

Q: Do the side effects of LevaMed get better over time?

Official documents note that gastrointestinal adverse reactions, such as nausea, are significantly more frequent during the first month of treatment. This pattern of occurrence may be interpreted to indicate that the frequency of these specific side effects lessens after the initial period.

Q: Is LevaMed taken with food or on an empty stomach?

Official documents state there is no known interaction with food. The tablets may be swallowed with a liquid, or they can be crushed and mixed with soft food, as described in the administration guidelines.

Q: Is it true that LevaMed takes several weeks to reach full effect?

The action of the medicine depends on its purpose. The anti-worm effect is rapid, often achieved after a single dose. However, the immunomodulatory effects, when used for chronic conditions, are associated with a long-term regimen and may require time to fully manifest.

Q: What is the 'mechanism of action' of LevaMed in simple terms?

The drug has a dual action. As an anti-worm agent, it works by rapidly paralyzing the target organism's muscles. Its role as an immunomodulator is described as helping to restore depressed immune functions by stimulating the activity of cells like T-cells and macrophages.

Q: How quickly should I expect to notice any effects from LevaMed?

According to official pharmacokinetic studies, the drug is absorbed rapidly after being taken orally. It is documented to reach its peak concentration in the bloodstream within 1.5 to 2 hours of administration.

Q: Is LevaMed available in a generic version?

The active ingredient, Levamisole, is available from multiple authorized manufacturers and is identified under various product numbers. This indicates that different product forms, including generic versions, may be available in the marketplace.

Q: Is there a different name for LevaMed in other countries?

Levamisole is the official International Nonproprietary Name (INN) for the active substance, which remains consistent globally across all regulatory documents. However, the commercial brand name under which it is marketed will vary from country to country.

Q: How long does LevaMed stay in your system after stopping treatment?

Pharmacokinetic data indicates that the medicine has a plasma elimination half-life of 3 to 4 hours. Approximately 70% of the drug is described as being eliminated from the system through the kidneys within three days following administration.

Q: Where can I find the official prescribing information for LevaMed?

Official prescribing information is made publicly available through government regulatory authority websites. Examples include DailyMed in the US (FDA) or the public access portals of the European Medicines Agency (EMA).

Q: What are the restrictions on driving or operating machinery while on LevaMed?

Official labeling advises that the medicine may cause symptoms such as dizziness and sleepiness in some patients. Official documentation advises that activities such as driving or operating machinery should be avoided if these specific effects are experienced while using the medication.

Q: Is LevaMed a new drug, or has it been around for a while?

The compound Levamisole is an established medicine that has been known and studied since the 1960s/1970s. It is noted in official texts as an older compound with a history of use in human and veterinary medicine.

Q: Does LevaMed have a warning label or 'Black Box' warning?

Due to its association with serious adverse effects, including agranulocytosis (a serious decrease in white blood cells), the labeling contains prominent warnings and precautions. These warnings are necessary to guide monitoring and management of the risks associated with its use.

Q: What is the difference between the brand name and generic LevaMed?

The brand name version is marketed under a specific commercial name, while the generic version contains the identical active ingredient, Levamisole hydrochloride. The difference is that the generic version may use different inactive ingredients (excipients).

Q: Do official documents mention any known overdose symptoms for LevaMed?

Official documents describe known symptoms of overdose. These may include specific effects such as nausea, vomiting, confusion, seizures, or extreme fatigue.

How should LevaMed be stored and disposed of?

How to Store and Dispose of LevaMed?

LevaMed (levamisole hydrochloride) must be maintained under specific conditions to ensure stability and safety, as detailed in official regulatory documents.

Official Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), permitting brief excursions up to 30 C.
Environment	Keep the container closed in a dry, cool place.
Prepared Solution Stability	Excess solution may be stored for up to 90 days in clean, tightly capped bottles at up to 25 C.
Child Safety	The product must be Stored locked up and kept out of reach of children (P405).

Disposal Instructions

Disposal of the contents and container must be carried out in accordance with local, regional, national, and international regulations (P501). It is required to avoid release to the environment and prevent the product from entering sewers or surface water.

LevaMed